Zongertinib is a newly approved oral targeted therapy for patients with unresectable or metastatic HER2-mutated non-squamous non-small cell lung cancer (NSCLC) who have received prior treatment. Approved by the FDA in August 2025, it is the first oral option specifically for this patient group, marking a significant advance in targeted lung cancer therapy.
Zongertinib works by selectively and irreversibly inhibiting HER2 while sparing wild-type EGFR, reducing common toxicities like rash and diarrhea. In the Phase 1b Beamion LUNG-1 trial, it showed a 71% response rate with durable outcomes and activity against brain metastases. The drug was generally well tolerated, with low discontinuation rates.
Common side effects include diarrhea, liver toxicity, rash, fatigue, and nausea, while serious risks include heart dysfunction and interstitial lung disease. Ongoing Phase 3 trials are evaluating its use as a first-line treatment, highlighting its strong potential in HER2-mutant NSCLC.